company background image
SLS

SELLAS Life Sciences Group NasdaqCM:SLS Stock Report

Last Price

US$2.16

Market Cap

US$44.4m

7D

2.9%

1Y

-75.2%

Updated

06 Oct, 2022

Data

Company Financials +
SLS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

SLS Stock Overview

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States.

SELLAS Life Sciences Group Competitors

Price History & Performance

Summary of all time highs, changes and price drops for SELLAS Life Sciences Group
Historical stock prices
Current Share PriceUS$2.16
52 Week HighUS$9.78
52 Week LowUS$1.92
Beta1.85
1 Month Change-26.78%
3 Month Change-17.56%
1 Year Change-75.20%
3 Year Change-65.02%
5 Year Changen/a
Change since IPO-99.36%

Recent News & Updates

Sep 20
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

SLSUS BiotechsUS Market
7D2.9%2.4%3.3%
1Y-75.2%-21.0%-20.4%

Return vs Industry: SLS underperformed the US Biotechs industry which returned -19.3% over the past year.

Return vs Market: SLS underperformed the US Market which returned -18.8% over the past year.

Price Volatility

Is SLS's price volatile compared to industry and market?
SLS volatility
SLS Average Weekly Movement8.8%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: SLS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: SLS's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201211Angelos Stergiouhttps://www.sellaslifesciences.com

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer.

SELLAS Life Sciences Group Fundamentals Summary

How do SELLAS Life Sciences Group's earnings and revenue compare to its market cap?
SLS fundamental statistics
Market CapUS$44.39m
Earnings (TTM)-US$38.84m
Revenue (TTM)US$1.00m

44.4x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SLS income statement (TTM)
RevenueUS$1.00m
Cost of RevenueUS$100.00k
Gross ProfitUS$900.00k
Other ExpensesUS$39.74m
Earnings-US$38.84m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.89
Gross Margin90.00%
Net Profit Margin-3,884.10%
Debt/Equity Ratio0%

How did SLS perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is SLS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SLS?

Other financial metrics that can be useful for relative valuation.

SLS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue18.5x
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does SLS's PS Ratio compare to its peers?

SLS PS Ratio vs Peers
The above table shows the PS ratio for SLS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average8.3x
CASI CASI Pharmaceuticals
1x50.5%US$36.5m
VTGN VistaGen Therapeutics
30.5x68.6%US$32.5m
TTOO T2 Biosystems
1.4x20.8%US$37.5m
CNTG Centogene
0.2x-72.0%US$31.1m
SLS SELLAS Life Sciences Group
44.4x89.0%US$44.4m

Price-To-Sales vs Peers: SLS is expensive based on its Price-To-Sales Ratio (44.4x) compared to the peer average (8.3x).


Price to Earnings Ratio vs Industry

How does SLS's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: SLS is expensive based on its Price-To-Sales Ratio (44.4x) compared to the US Biotechs industry average (14x)


Price to Sales Ratio vs Fair Ratio

What is SLS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SLS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio44.4x
Fair PS Ratio40.8x

Price-To-Sales vs Fair Ratio: SLS is expensive based on its Price-To-Sales Ratio (44.4x) compared to the estimated Fair Price-To-Sales Ratio (40.8x).


Share Price vs Fair Value

What is the Fair Price of SLS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SLS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SLS's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is SELLAS Life Sciences Group forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


36.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SLS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SLS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SLS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SLS's revenue (89% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: SLS's revenue (89% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SLS's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has SELLAS Life Sciences Group performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


4.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SLS is currently unprofitable.

Growing Profit Margin: SLS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SLS is unprofitable, but has reduced losses over the past 5 years at a rate of 4% per year.

Accelerating Growth: Unable to compare SLS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SLS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: SLS has a negative Return on Equity (-203.81%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is SELLAS Life Sciences Group's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SLS's short term assets ($28.7M) exceed its short term liabilities ($12.2M).

Long Term Liabilities: SLS's short term assets ($28.7M) exceed its long term liabilities ($967.0K).


Debt to Equity History and Analysis

Debt Level: SLS is debt free.

Reducing Debt: SLS currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SLS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SLS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 6.1% each year


Discover healthy companies

Dividend

What is SELLAS Life Sciences Group current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

SELLAS Life Sciences Group Dividend Yield vs Market
How does SELLAS Life Sciences Group dividend yield compare to the market?
SegmentDividend Yield
Company (SELLAS Life Sciences Group)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (SELLAS Life Sciences Group)n/a

Notable Dividend: Unable to evaluate SLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SLS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SLS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SLS's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SLS has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average management tenure


CEO

Angelos Stergiou (46 yo)

9.83yrs

Tenure

US$1,833,917

Compensation

Dr. Angelos M. Stergiou, MD, ScD h.c., is the Founder, President, Chief Executive Officer and Director of SELLAS Life Sciences Group, Inc. (formerly known as SELLAS Life Sciences Group AG) (formerly, Sella...


CEO Compensation Analysis

Angelos Stergiou's Compensation vs SELLAS Life Sciences Group Earnings
How has Angelos Stergiou's remuneration changed compared to SELLAS Life Sciences Group's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$39m

Mar 31 2022n/an/a

-US$35m

Dec 31 2021US$2mUS$565k

-US$21m

Sep 30 2021n/an/a

-US$18m

Jun 30 2021n/an/a

-US$15m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$1mUS$541k

-US$17m

Sep 30 2020n/an/a

-US$21m

Jun 30 2020n/an/a

-US$28m

Mar 31 2020n/an/a

-US$27m

Dec 31 2019US$1mUS$630k

-US$28m

Sep 30 2019n/an/a

-US$34m

Jun 30 2019n/an/a

-US$32m

Mar 31 2019n/an/a

-US$36m

Dec 31 2018US$1mUS$549k

-US$41m

Sep 30 2018n/an/a

-US$37m

Jun 30 2018n/an/a

-US$32m

Mar 31 2018n/an/a

-US$30m

Dec 31 2017US$729kUS$400k

-US$24m

Compensation vs Market: Angelos's total compensation ($USD1.83M) is above average for companies of similar size in the US market ($USD772.75K).

Compensation vs Earnings: Angelos's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: SLS's management team is considered experienced (4.6 years average tenure).


Board Members

Experienced Board: SLS's board of directors are considered experienced (5.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqCM:SLS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
02 Dec 21SellUS$1,448John BurnsIndividual231US$6.27
02 Dec 21SellUS$5,298Barbara WoodIndividual847US$6.25
02 Dec 21SellUS$13,252Angelos StergiouIndividual2,120US$6.25

Ownership Breakdown

What is the ownership structure of SLS?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders45,6210.2%
Institutions2,995,12614.6%
General Public17,511,17185.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.5%.


Top Shareholders

Top 25 shareholders own 14.76% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
4.52%
Empery Asset Management, LP
927,984$2.0m0%18%
4.04%
The Vanguard Group, Inc.
830,119$1.8m26.37%no data
1.25%
BlackRock, Inc.
257,505$556.2k1.82%no data
1.24%
Alyeska Investment Group, L.P.
254,018$548.7k0%0.01%
0.7%
Geode Capital Management, LLC
144,719$312.6k5.71%no data
0.54%
Equitable Holdings, Inc, Asset Management Arm
110,000$237.6k5.77%no data
0.49%
Highbridge Capital Management, LLC
100,000$216.0k0%no data
0.45%
Morgan Stanley, Investment Banking and Brokerage Investments
91,471$197.6k0.19%no data
0.25%
State Street Global Advisors, Inc.
51,236$110.7k0%no data
0.18%
Citadel Advisors LLC
37,639$81.3k181.52%no data
0.16%
Renaissance Technologies LLC
33,838$73.1k0%no data
0.13%
John Burns
27,244$58.8k0%no data
0.12%
Northern Trust Global Investments
24,605$53.1k-0.87%no data
0.12%
Bank of America Corporation, Asset Management Arm
24,268$52.4k12.06%no data
0.1%
Two Sigma Investments, LP
21,494$46.4k0%no data
0.099%
BNY Mellon Asset Management
20,247$43.7k-3.48%no data
0.083%
T. Rowe Price Group, Inc.
17,100$36.9k0%no data
0.064%
Angelos Stergiou
13,233$28.6k-91.99%no data
0.057%
Susquehanna Fundamental Investments, LLC
11,706$25.3k0%no data
0.054%
Wells Fargo & Company, Securities and Brokerage Investments
11,000$23.8k83.33%no data
0.049%
Point72 Asset Management, L.P.
10,100$21.8k0%no data
0.018%
Tower Research Capital LLC
3,755$8.1k709.27%no data
0.017%
JPMorgan Chase & Co, Brokerage and Securities Investments
3,550$7.7k0%no data
0.016%
Lord, Abbett & Co. LLC
3,201$6.9k0%no data
0.013%
Victory Capital Management Inc.
2,684$5.8k31.38%no data

Company Information

SELLAS Life Sciences Group, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: SELLAS Life Sciences Group, Inc.
  • Ticker: SLS
  • Exchange: NasdaqCM
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$44.392m
  • Shares outstanding: 20.55m
  • Website: https://www.sellaslifesciences.com

Number of Employees


Location

  • SELLAS Life Sciences Group, Inc.
  • Times Square Tower
  • Suite 2503
  • New York
  • New York
  • 10036
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RXK3DB (Deutsche Boerse AG)YesCommon SharesDEEURJan 2018
SLSNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDJan 2018

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/06 00:00
End of Day Share Price2022/10/06 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.